2/29
06:42 am
harp
Merck: A High-Conviction Investment For Long-Term Growth [Seeking Alpha]
Low
Report
Merck: A High-Conviction Investment For Long-Term Growth [Seeking Alpha]
2/26
12:16 pm
harp
Harpoon Therapeutics, Inc. (NASDAQ: HARP) had its "neutral" rating re-affirmed by analysts at Citigroup Inc.. They now have a $23.00 price target on the stock, up previously from $13.00.
Low
Report
Harpoon Therapeutics, Inc. (NASDAQ: HARP) had its "neutral" rating re-affirmed by analysts at Citigroup Inc.. They now have a $23.00 price target on the stock, up previously from $13.00.